TTMV::RARA驱动急性早幼粒细胞白血病的流行病学、临床特征及分子基础
本文首次系统描述TTMV::RARA融合基因驱动的急性早幼粒细胞白血病(APL)新亚型。该亚型在儿童中更常见,是仅次于PML::RARA的第二常见维A酸受体融合;髓外受累尤其是髓系肉瘤发生率高,常伴i(17)(q10)或7q22及表观遗传调控基因突变。多数患者获初始缓解但复发常见,复发与快速获得全反式维A酸(ATRA)耐药突变及继发化疗耐药相关;含维奈克拉方案显示令人鼓舞的临床疗效。病毒整合一致发生在RARA内含子2,由微同源重组介导,整合病毒启动子内的串联RUNX1结合基序可能解释嗜髓性。
要点
- TTMV::RARA是儿童中更常见的APL亚型,为仅次于PML::RARA的第二常见维A酸受体融合。
- 髓外受累(尤其髓系肉瘤)发生率高,52.0%病例伴i(17)(q10)或7q22。
- 多数获初始缓解但复发常见,含维奈克拉方案显示令人鼓舞的临床疗效。
核心结论
- TTMV::RARA-APL为一种独特的白血病实体,为病毒介导的白血病发生及治疗策略研究奠定基础。
研究设计与样本
- 对TTMV::RARA驱动APL的流行病学特征、临床表现、病毒学特征及分子机制进行首次全面描述。
主要发现
- TTMV::RARA在儿童患者中更常见,为仅次于PML::RARA的第二常见维A酸受体融合。
- 患者髓外受累发生率高,尤其髓系肉瘤。
- 52.0%病例检出涉及i(17)(q10)或7q22的细胞遗传学异常,多呈互斥方式。
- 76.9%患者存在表观遗传调控基因的共突变。
- 多数患者获初始缓解但复发常见,复发与快速获得ATRA耐药突变及继发化疗耐药相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Integration of torque teno mini virus (TTMV) generating the TTMV::RARA (retinoic acid receptor α) fusion represents a newly recognized subtype of acute promyelocytic leukemia (APL) that merits detailed investigation. We present, to our knowledge, the first comprehensive characterization of its epidemiologic profile, clinical presentation, virologic characteristics, and underlying molecular mechanisms. Our findings indicate that TTMV::RARA is more prevalent in pediatric patients and represents the second most common retinoic acid receptor fusion after PML::RARA. Affected patients exhibit a high incidence of extramedullary involvement, particularly myeloid sarcoma. Cytogenetic abnormalities involving i(17)(q10) or 7q22 were identified in 52.0% of cases, largely in a mutually exclusive manner. Co-occurring mutations in epigenetic regulators were present in 76.9% of patients. Although most patients achieved initial remission, relapse was common and associated with rapid acquisition of all-trans retinoic acid (ATRA)-resistant mutation and secondary chemoresistance. Venetoclax-containing regimens demonstrated encouraging clinical efficacy. Phylogenetic analysis indicated that patient-derived TTMV strains clustered into a distinct clade. TTMV integration consistently occurred within RARA intron 2, involving a consensus fragment of 510 to 610 base pairs encompassing the viral promoter and open reading frame 2 (ORF2) N terminus, likely mediated by microhomology-driven recombination. Tandem RUNX1-binding motifs within the integrated viral promoter may underlie the myelotropism of these TTMV strains and facilitate transcriptional activation of TTMV::RARA. The chimeric protein retains at least the first 56 N-terminal residues of ORF2 and remains transcriptionally responsive to pharmacological concentrations of ATRA. These findings establish TTMV::RARA-APL as a distinct leukemia entity, laying the foundation for future studies on virus-mediated leukemogenesis and therapeutic strategies.
引用
- Zhou X, Chen J, Tang YL, et al. Epidemiology, clinical features, and molecular basis of TTMV::RARA-driven acute promyelocytic leukemia. Blood. 2025. PMID: 40811852. doi:10.1182/blood.2025028674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。